TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Key facts
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Where
- France20 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 192 people enrolled
- Started
- 24 Mar 2019
- Ended
- 4 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Liberal Red blood cell transfusion
- Restrictive Red blood cell transfusion
- Record updated
- 25 June 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age > 18 years
- Evolutive (complete remission < 2 years) malignant solid tumor or chronic or acute hematological malignancy
- Septic shock defined as:
- Presumed or documented infection
- Acute circulatory failure defined as hypotension requirement of vasoactive drugs for more than one hour (norepinephrine or epinephrine ≥ 0.1 µg/kg/min)
- Tissue hypoxia defined by arterial lactate level > 2 mmol/L within 3 hours prior to inclusion
- Hemoglobin level < 9 g/dL
- Informed consent from patients or surrogates
Who cannot take part
- Acute life-threatening bleeding
- Ongoing acute coronary syndrome or any other acute ischemic condition
- End-of-life decisions at the time of ICU admission
- Refusal of transfusions for personal beliefs
- Lack of social security coverage
- Pregnancy or breastfeeding
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Septic shock is a frequent complication associated with high mortality in patients with malignancies. The best transfusion strategy (restrictive or liberal) for the resuscitation of septic shock remains a controversial issue, in relation with potentially discrepant goals of tissue oxygenation and transfusion sparing.
Read full original descriptionShow less
In this study, the investigators propose to address the efficacy of two RBC transfusion strategies (liberal or restrictive) in restoring appropriate tissue oxygenation as well as their tolerance.
The investigators designed a prospective randomized multicenter trial aimed at comparing liberal and restrictive RBC transfusion strategies applied during the first 48 hours of resuscitation in cancer patients with septic shock and anemia.
The 2 groups in the trial
- Liberal strategyExisting treatment, for comparison
Maintain a hemoglobin level \> 9 g/dL during the first 48 hours of resuscitation of septic shock
Treatment: Liberal Red blood cell transfusion
- Restrictive strategyTreatment being tested
Maintain a hemoglobin level \> 7 g/dL during the resuscitation of septic shock
Treatment: Restrictive Red blood cell transfusion
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Stratégie Transfusionnelle érythrocytaire Dans la réanimation du Choc Septique du Patient d'Onco-hématologie : Essai randomisé Multicentrique TRANSPORT [TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock]
- Publications
- Record updated
- 25 June 2024